2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1576

Identifying Subgroups of Rheumatoid Arthritis Patients Based On Levels of Pain, Disability, and Depression
Abstract Number: 1435

Identifying Systemic Lupus Erythematosus Patients At Higher Risk of Coronary Artery Disease
Abstract Number: 1253

Identifying Vulnerable Plaque in Rheumatoid Arthritis: A Pilot Study Using Novel Microbubble-Contrast Enhanced Carotid Ultrasonography
Abstract Number: 205

Idiopathic Inflammatory Myositis Is Associated with an Increased Incidence of Systemic Sclerosis
Abstract Number: 233

IFN Signature Is Associated with Autoantibody Profiles in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 752

IFNg Production Is Intimately Associated with Clinical and Laboratory Features of CpG-Induced Secondary Hemophagocytic Lymphohistiocytosis (sHLH)/Macrophage Activating Syndrome (MAS) in Mice
Abstract Number: 1731

IgA Anti-β₂glycoprotein I Antibodies Are Pathogenic in a Mouse Model of APS
Abstract Number: 2200

IgE Autoantibodies Against SSA and SSB in Patients with Sjögren’s Syndrome and Healthy Controls
Abstract Number: 1534

IgG4 Plasma Cell Infiltration in Granulomatosis with Polyangiitis (formerly Wegener’s) Lung Biopsies
Abstract Number: 682

IL-12p70 Levels Play a Role in Damage Accrual in SLE Patients
Abstract Number: 1492

IL-13 Receptors and Signaling in the Dermal Fibroblasts From Patients with Systemic Sclerosis
Abstract Number: 2491

IL-17 Expression Is Low in Psoriatic Arthritis Synovium Compared to Expression in Matched Skin Lesions
Abstract Number: 2519

IL-1β and TNF-α Regulate the Global and Locus-Specific hydroxymethylation of Genomic DNA by Modulating the Expression and Activity of Tet-1 in Human OA Chondrocytes
Abstract Number: 2080

IL-20 Is Not Involved in Mouse Collagen Induced Arthritis
Abstract Number: 1192

IL-21 Regulates B Cell Proliferation and Differentiation in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].